# EP-104 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ep-104

> The next catalyst for EP-104, sponsored by EUPRAXIA PHARMACEUTICALS INC. (EPRX), is its interim data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | EP-104 |
| Codes | EP-104 |
| Sponsor | EUPRAXIA PHARMACEUTICALS INC. (EPRX) https://sec-api.dev/companies/eprx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 26, 2023: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-05-12, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455405): "Top-line data readout was positive, and was announced on June 26, 2023." https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345045): "Top-line data readout was positive, and was announced on June 26, 2023." https://www.sec.gov/Archives/edgar/data/1581178/000119312526345045/d153391dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219802): "Top-line data readout was positive, and was announced on June 26, 2023." https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm

### July 7, 2025: trial start

- Status: completed. Date confidence: exact.
- First seen 2025-08-13, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455405): "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345045): "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." https://www.sec.gov/Archives/edgar/data/1581178/000119312526345045/d153391dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219802): "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-264619): "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." https://www.sec.gov/Archives/edgar/data/1581178/000119312525264619/d35661dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179135): "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex992.htm

### August 12, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-08-13, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179135): "Announced first patient dosed in the Phase 2b placebo-controlled portion of the" https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex993.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-08-13, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-264619): "Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026" https://www.sec.gov/Archives/edgar/data/1581178/000119312525264619/d35661dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-264619): "Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1581178/000119312525264619/d35661dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179135): "Topline data from the Phase 2b portion of the RESOLVE study is expected to be available in H2 2026." https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-179135): "EP-104GI RESOLVE trial with topline data expected in H2 2026" https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex993.htm

### Dec 2026: interim data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-05-12, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455405): "In December 2026, the Company expects to release interim data from the Phase 2b portion of the RESOLVE study." https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455405): "Interim data from the Phase 2b portion of the RESOLVE study is expected to be available in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345045): "In Q4 2026, the Company expects to release interim data from the Phase 2b portion of the" https://www.sec.gov/Archives/edgar/data/1581178/000119312526345045/d153391dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219802): "In Q4 2026, the Company expects to release interim data from the Phase 2b portion of the" https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219802): "Interim data from the Phase 2b portion of the RESOLVE study is expected to be available in Q4 2026." https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007331): "Phase 2b interim analysis expected in December 2026" https://www.sec.gov/Archives/edgar/data/1581178/000117184326007331/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007331): "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000117184326007331/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455405): "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006648): "Interim analysis of the Phase 2b portion of the study is on track for December 2026" https://www.sec.gov/Archives/edgar/data/1581178/000117184326006648/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006648): "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000117184326006648/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006551): "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000117184326006551/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006307): "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026." https://www.sec.gov/Archives/edgar/data/1581178/000117184326006307/exh_991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ep-104.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EP-104 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ep-104

```bibtex
@misc{secapidev_pdufa_ep_104_20261116,
  title        = {EP-104 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ep-104}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ep_104_20261116","title":"EP-104 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ep-104","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
